Seeking Alpha

Investors frown on Fibrocell Science's public offering

  • Fibrocell Science (FCSC) slips after announcing a public offering with a 15% underwriter option.
  • Proceeds will go towards trials for new azficel-T indications — the cell-based product is currently approved for "smile lines". (PR)
  • Shares -14% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)